{
  "id": 18003426,
  "title": "Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data",
  "url": "https://urgent.news/2026/11/03/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T18:33:50.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/artificial-intelligence/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data/"
  },
  "original_language": "en",
  "account": "Recursion anticipates launching its first registrational trial in the second half of 2027 for its lead candidate REC-4881, following positive mid-stage clinical data from the Phase Ib/II TUPELO trial. The trial, which generated encouraging results, demonstrated reductions in both larger, higher-risk polyps and lower GI polyp burden in most patients treated with REC-4881. This oral therapy represents a significant advancement in the treatment of familial adenomatous polyposis (FAP), a rare genetic disorder that currently has no approved pharmacologic therapies. REC-4881 is a first-in-class, oral allosteric inhibitor of MEK1 and MEK2, and its development was facilitated through a global licensing agreement with Takeda Pharmaceutical. The drug's anticipated second half 2027 timing for a registrational trial will depend on discussions with the FDA.",
  "summary": "Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [
    "Recursion plans H2 2027 pivotal trial for REC-4881 after positive Phase II data",
    "REC-4881 reduces larger polyps and lowers GI polyp burden in FAP patients",
    "Oral inhibitor of MEK1 and MEK2 developed via Takeda licensing agreement"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}